ArticleFrontiers in oncology2022
A phase II study of buparlisib in relapsed or refractory thymomas.
Mohammad I Abu Zaid et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this papercites it
ArticleFrontiers in oncology2022
Mohammad I Abu Zaid et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.